Chemotherapy in Pancreatic Cancer: A Systematic Review

Leva Hajatdoost, Keyvan Sedaghat, Erin J. Walker, Jackson Thomas, Sam Kosari

Research output: Contribution to journalArticle

5 Citations (Scopus)
4 Downloads (Pure)

Abstract

Background and Aim: Pancreatic cancer is one of the most fatal cancers. Cytotoxic chemotherapy remains the mainstream treatment for unresectable pancreatic cancer. This systematic review evaluated and compared the overall survival (OS) and progression-free survival (PFS) outcomes obtained from recent phase 2 and 3 clinical trials of pancreatic cancer chemotherapy. Materials and methods: Thirty-two studies were included and compared based on chemotherapy agents or combinations used. Additionally, outcomes of first-line versus second-line chemotherapy in pancreatic cancer were compared. Results: In studies that investigated the treatments in adjuvant settings, the highest OS reported was for S-1 in patients, who received prior surgical resection
(46.5 months). In neoadjuvant settings, the combination of gemcitabine, docetaxel, and capecitabine prior to the surgical resection had promising outcomes (OS of 32.5 months). In non-adjuvant settings, the highest OS reported was for the combination of temsirolimus plus bevacizumab (34.0 months). Amongst studies that investigated second-line treatment, the highest OS reported was for the combination of gemcitabine plus cisplatin (35.5 months), then temsirolimus plus bevacizumab (34.0 months). Conclusions: There is a need to develop further strategies besides chemotherapy to improve the outcomes in pancreatic cancer treatment. Future studies should consider surgical interventions, combination chemotherapy, and individualized second-line treatment based on the prior chemotherapy.
Original languageEnglish
Article number48
Pages (from-to)1-17
Number of pages17
JournalMedicina
Volume54
Issue number3
DOIs
Publication statusPublished - Jul 2018

Cite this

Hajatdoost, Leva ; Sedaghat, Keyvan ; Walker, Erin J. ; Thomas, Jackson ; Kosari, Sam. / Chemotherapy in Pancreatic Cancer: A Systematic Review. In: Medicina. 2018 ; Vol. 54, No. 3. pp. 1-17.
@article{4eaca595f72648ab8021f64410373b1c,
title = "Chemotherapy in Pancreatic Cancer: A Systematic Review",
abstract = "Background and Aim: Pancreatic cancer is one of the most fatal cancers. Cytotoxic chemotherapy remains the mainstream treatment for unresectable pancreatic cancer. This systematic review evaluated and compared the overall survival (OS) and progression-free survival (PFS) outcomes obtained from recent phase 2 and 3 clinical trials of pancreatic cancer chemotherapy. Materials and methods: Thirty-two studies were included and compared based on chemotherapy agents or combinations used. Additionally, outcomes of first-line versus second-line chemotherapy in pancreatic cancer were compared. Results: In studies that investigated the treatments in adjuvant settings, the highest OS reported was for S-1 in patients, who received prior surgical resection(46.5 months). In neoadjuvant settings, the combination of gemcitabine, docetaxel, and capecitabine prior to the surgical resection had promising outcomes (OS of 32.5 months). In non-adjuvant settings, the highest OS reported was for the combination of temsirolimus plus bevacizumab (34.0 months). Amongst studies that investigated second-line treatment, the highest OS reported was for the combination of gemcitabine plus cisplatin (35.5 months), then temsirolimus plus bevacizumab (34.0 months). Conclusions: There is a need to develop further strategies besides chemotherapy to improve the outcomes in pancreatic cancer treatment. Future studies should consider surgical interventions, combination chemotherapy, and individualized second-line treatment based on the prior chemotherapy.",
keywords = "chemotherapy, pancreatic cancer, first-line treatment, second-line treatment, survival",
author = "Leva Hajatdoost and Keyvan Sedaghat and Walker, {Erin J.} and Jackson Thomas and Sam Kosari",
year = "2018",
month = "7",
doi = "10.3390/medicina54030048",
language = "English",
volume = "54",
pages = "1--17",
journal = "Medicina",
issn = "1010-660X",
publisher = "Kauno Medicinos Universitetas",
number = "3",

}

Chemotherapy in Pancreatic Cancer: A Systematic Review. / Hajatdoost, Leva; Sedaghat, Keyvan; Walker, Erin J.; Thomas, Jackson; Kosari, Sam.

In: Medicina, Vol. 54, No. 3, 48, 07.2018, p. 1-17.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Chemotherapy in Pancreatic Cancer: A Systematic Review

AU - Hajatdoost, Leva

AU - Sedaghat, Keyvan

AU - Walker, Erin J.

AU - Thomas, Jackson

AU - Kosari, Sam

PY - 2018/7

Y1 - 2018/7

N2 - Background and Aim: Pancreatic cancer is one of the most fatal cancers. Cytotoxic chemotherapy remains the mainstream treatment for unresectable pancreatic cancer. This systematic review evaluated and compared the overall survival (OS) and progression-free survival (PFS) outcomes obtained from recent phase 2 and 3 clinical trials of pancreatic cancer chemotherapy. Materials and methods: Thirty-two studies were included and compared based on chemotherapy agents or combinations used. Additionally, outcomes of first-line versus second-line chemotherapy in pancreatic cancer were compared. Results: In studies that investigated the treatments in adjuvant settings, the highest OS reported was for S-1 in patients, who received prior surgical resection(46.5 months). In neoadjuvant settings, the combination of gemcitabine, docetaxel, and capecitabine prior to the surgical resection had promising outcomes (OS of 32.5 months). In non-adjuvant settings, the highest OS reported was for the combination of temsirolimus plus bevacizumab (34.0 months). Amongst studies that investigated second-line treatment, the highest OS reported was for the combination of gemcitabine plus cisplatin (35.5 months), then temsirolimus plus bevacizumab (34.0 months). Conclusions: There is a need to develop further strategies besides chemotherapy to improve the outcomes in pancreatic cancer treatment. Future studies should consider surgical interventions, combination chemotherapy, and individualized second-line treatment based on the prior chemotherapy.

AB - Background and Aim: Pancreatic cancer is one of the most fatal cancers. Cytotoxic chemotherapy remains the mainstream treatment for unresectable pancreatic cancer. This systematic review evaluated and compared the overall survival (OS) and progression-free survival (PFS) outcomes obtained from recent phase 2 and 3 clinical trials of pancreatic cancer chemotherapy. Materials and methods: Thirty-two studies were included and compared based on chemotherapy agents or combinations used. Additionally, outcomes of first-line versus second-line chemotherapy in pancreatic cancer were compared. Results: In studies that investigated the treatments in adjuvant settings, the highest OS reported was for S-1 in patients, who received prior surgical resection(46.5 months). In neoadjuvant settings, the combination of gemcitabine, docetaxel, and capecitabine prior to the surgical resection had promising outcomes (OS of 32.5 months). In non-adjuvant settings, the highest OS reported was for the combination of temsirolimus plus bevacizumab (34.0 months). Amongst studies that investigated second-line treatment, the highest OS reported was for the combination of gemcitabine plus cisplatin (35.5 months), then temsirolimus plus bevacizumab (34.0 months). Conclusions: There is a need to develop further strategies besides chemotherapy to improve the outcomes in pancreatic cancer treatment. Future studies should consider surgical interventions, combination chemotherapy, and individualized second-line treatment based on the prior chemotherapy.

KW - chemotherapy

KW - pancreatic cancer

KW - first-line treatment

KW - second-line treatment

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85053303487&partnerID=8YFLogxK

UR - http://www.mendeley.com/research/chemotherapy-pancreatic-cancer-systematic-review

U2 - 10.3390/medicina54030048

DO - 10.3390/medicina54030048

M3 - Article

VL - 54

SP - 1

EP - 17

JO - Medicina

JF - Medicina

SN - 1010-660X

IS - 3

M1 - 48

ER -